Observing cancer and serious infection risks in people with inflammatory bowel disease
Follows adults with Crohn disease or ulcerative colitis treated with newer medicines over time.
Plain-language title generated from the registry record
Registry title: Ibd CAncer and seRious Infections in France (I-CARE 2)
Key facts
- Where
- Amiens and Paris, FranceSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06089590, who can take part
Where in France
- Chu Amiens PicardieAmiens, FranceTaking people
- APHP - Hôpital Saint AntoineParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- Trial code
- NCT06089590
- Record updated
- 6 November 2026
- Original description
This is a French prospective longitudinal observational multicentre cohort study.Read full original descriptionShow less
Ibd CAncer and seRious Infections in France (I-CARE 2)
This is a French prospective longitudinal observational multicentre cohort study.
Primary objective : to assess prospectively the presence and the extent of safety concerns (cancer, serious infections, arterial and venous thrombotic events) in patients with CD and UC and treated with JAKi, anti-IL23p19, and S1p modulators.
Inclusion: Patient with an established diagnosis of Crohn's disease, ulcerative colitis or IBD unclassified based on usual radiological, endoscopic or histological criteria; Patient aged 18 and older accepting to sign the informed participating consent form, stating that he accepts to provide personal details (mobile and home phone number, e-mail address), to complete the e-PRO as required and to be contacted by a Study Coordinator and his gastroenterologist for the purpose of the study during the entire study period and during follow up if required.
Exclusion: Patient enrolled in a Randomized Clinical Trial (If the investigational product received was blinded, and if the treatment is unknown at time of enrolment in I-CARE 2); Patient unable to sign the informed consent form; Patient with no regular access to internet; Patient refusing to sign the informed consent form.